BIOLASE Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Biolase (BIOL) Tops Q1 EPS by 3c
May 7, 2020 5:43 PM EDTBiolase (NASDAQ: BIOL) reported Q1 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $4.7 million versus the consensus estimate of $4.98 million.
"Our go-to-market strategy was demonstrating meaningful progress prior to the COVID-19 pandemic, reflecting the changes we made throughout 2019 to better align our business and operating... More



